ALKS insider buying and SEC filings, explained
Alkermes plc. · CIK 1520262
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Company profile
- Exchanges
- Nasdaq
- Industry (SIC)
- Pharmaceutical Preparations
- Fiscal year end
- Dec 31
- Former names
- ANTLER SCIENCE TWO PLC; Antler Science Two Ltd
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$0
Planned sales (10b5-1)
$7.4M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Oct 2, 2026 | Planned (10b5-1) | David Joseph Gaffin (EVP, CLO, Alkermes, Inc.) sold 2,034 shares at $41.03 ($83K), marked as a 10b5-1 plan trade. Holdings down 1% to 221,388 shares. | SEC filing Filed Oct 2, 2026, 6:22 PM ET |
| Sep 3, 2026 | Planned (10b5-1) | David Joseph Gaffin (EVP, CLO, Alkermes, Inc.) sold 2,034 shares at $48.01 ($98K), marked as a 10b5-1 plan trade. Holdings down 1% to 223,422 shares. | SEC filing Filed Sep 3, 2026 |
| Sep 1, 2026 | Planned (10b5-1) | Craig C. Hopkinson (EVP R&D, Chief Medical Officer) sold 9,000 shares at about $46.99 ($423K), marked as a 10b5-1 plan trade. Holdings down 12% to 65,389 shares. | SEC filing Filed Sep 1, 2026 |
| Aug 17, 2026 | Planned (10b5-1) | Christian Todd Nichols (SVP, Chief Commercial Officer) sold 7,576 shares at about $49.23 ($373K), marked as a 10b5-1 plan trade. Holdings down 7% to 102,193 shares. | SEC filing Filed Aug 17, 2026 |
| Aug 3, 2026 | Planned (10b5-1) | Craig C. Hopkinson (EVP R&D, Chief Medical Officer) sold 9,000 shares at $48.58 ($437K), marked as a 10b5-1 plan trade. Holdings down 11% to 69,389 shares. | SEC filing Filed Aug 3, 2026 |
| Aug 3, 2026 | Planned (10b5-1) | David Joseph Gaffin (EVP, CLO, Alkermes, Inc.) sold 2,034 shares at $48.58 ($99K), marked as a 10b5-1 plan trade. Holdings down 1% to 225,456 shares. | SEC filing Filed Aug 3, 2026 |
| Jul 6, 2026 | Planned (10b5-1) | David Joseph Gaffin (EVP, CLO, Alkermes, Inc.) sold 2,034 shares at $54.03 ($110K), marked as a 10b5-1 plan trade. Holdings down 1% to 227,490 shares. | SEC filing Filed Jul 6, 2026 |
| Jul 1, 2026 | Planned (10b5-1) | Craig C. Hopkinson (EVP R&D, Chief Medical Officer) sold 9,000 shares at about $51.51 ($464K), marked as a 10b5-1 plan trade. Holdings down 11% to 73,389 shares. | SEC filing Filed Jul 1, 2026 |
| Jun 12, 2026 | Planned (10b5-1) | Christopher I Wright (Director) sold 2,000 shares at $45.10 ($90K), marked as a 10b5-1 plan trade. Holdings down 7% to 25,680 shares. | SEC filing Filed Jun 12, 2026 |
| Jun 4, 2026 | Planned (10b5-1) | David Joseph Gaffin (EVP, CLO, Alkermes, Inc.) sold 2,034 shares at $43.05 ($88K), marked as a 10b5-1 plan trade. Holdings down 1% to 229,524 shares. | SEC filing Filed Jun 4, 2026 |
| Jun 1, 2026 | Planned (10b5-1) | Craig C. Hopkinson (EVP R&D, Chief Medical Officer) sold 9,000 shares at about $41.67 ($375K), marked as a 10b5-1 plan trade. Holdings down 10% to 77,389 shares. | SEC filing Filed Jun 1, 2026 |
| May 4, 2026 | Planned (10b5-1) | David Joseph Gaffin (EVP, CLO, Alkermes, Inc.) sold 2,034 shares at $33.20 ($68K), marked as a 10b5-1 plan trade. Holdings down 1% to 231,558 shares. | SEC filing Filed May 4, 2026 |
| May 1, 2026 | Planned (10b5-1) | Craig C. Hopkinson (EVP R&D, Chief Medical Officer) sold 9,000 shares at about $33.40 ($301K), marked as a 10b5-1 plan trade. Holdings down 10% to 81,389 shares. | SEC filing Filed May 1, 2026 |
| Apr 6, 2026 | Planned (10b5-1) | David Joseph Gaffin (EVP, CLO, Alkermes, Inc.) sold 2,034 shares at $34.57 ($70K), marked as a 10b5-1 plan trade. Holdings down 1% to 233,592 shares. | SEC filing Filed Apr 6, 2026 |
| Apr 1, 2026 | Planned (10b5-1) | Craig C. Hopkinson (EVP R&D, Chief Medical Officer) sold 9,000 shares at about $35.51 ($320K), marked as a 10b5-1 plan trade. Holdings down 10% to 85,389 shares. | SEC filing Filed Apr 1, 2026 |
| Mar 2, 2026 | Planned (10b5-1) | Samuel Joseph Parisi (VP, Finance (Interim PAO)) sold 6,890 shares at $29.29 ($202K), marked as a 10b5-1 plan trade. Holdings down 47% to 7,717 shares. | SEC filing Filed Mar 4, 2026 |
| Mar 2, 2026 | Planned (10b5-1) | Christian Todd Nichols (SVP, Chief Commercial Officer) sold 6,000 shares at $30.00 ($180K), marked as a 10b5-1 plan trade. Holdings down 5% to 109,769 shares. | SEC filing Filed Mar 4, 2026 |
| Mar 2, 2026 | Planned (10b5-1) | Craig C. Hopkinson (EVP R&D, Chief Medical Officer) sold 9,000 shares at about $29.72 ($267K), marked as a 10b5-1 plan trade. Holdings down 9% to 89,389 shares. | SEC filing Filed Mar 4, 2026 |
| Mar 2–3, 2026 | Planned (10b5-1) | David Joseph Gaffin (EVP, CLO, Alkermes, Inc.) sold 4,068 shares between Mar 2 and Mar 3 at about $29.53 ($120K), marked as a 10b5-1 plan trade. Holdings down 2% to 235,626 shares. | SEC filing Filed Mar 4, 2026 |
| Feb 2, 2026 | Planned (10b5-1) | Craig C. Hopkinson (EVP R&D, Chief Medical Officer) sold 9,000 shares at about $33.93 ($305K), marked as a 10b5-1 plan trade. Holdings down 13% to 57,740 shares. | SEC filing Filed Feb 2, 2026 |
| Feb 2, 2026 | Planned (10b5-1) | Shane Cooke (Director) sold 61,200 shares at about $34.57 ($2.1M), marked as a 10b5-1 plan trade. Holdings down 37% to 103,744 shares. | SEC filing Filed Feb 2, 2026 |
| Jan 8, 2026 | Planned (10b5-1) | Craig C. Hopkinson (EVP R&D, Chief Medical Officer) sold 5,000 shares at about $30.00 ($150K), marked as a 10b5-1 plan trade. Holdings down 7% to 61,740 shares. | SEC filing Filed Jan 8, 2026 |
| Jan 2, 2026 | Planned (10b5-1) | Craig C. Hopkinson (EVP R&D, Chief Medical Officer) sold 4,000 shares at $28.00 ($112K), marked as a 10b5-1 plan trade. Holdings down 6% to 61,740 shares. | SEC filing Filed Jan 2, 2026 |
| Dec 3, 2025 | Planned (10b5-1) | Craig C. Hopkinson (EVP R&D, Chief Medical Officer) sold 3,748 shares at about $30.00 ($112K), marked as a 10b5-1 plan trade. Holdings down 5% to 65,740 shares. | SEC filing Filed Dec 5, 2025 |
| Dec 1, 2025 | Planned (10b5-1) | Craig C. Hopkinson (EVP R&D, Chief Medical Officer) sold 4,000 shares at $29.30 ($117K), marked as a 10b5-1 plan trade. Holdings down 6% to 65,740 shares. | SEC filing Filed Dec 1, 2025 |
| Nov 3, 2025 | Planned (10b5-1) | Craig C. Hopkinson (EVP R&D, Chief Medical Officer) sold 9,000 shares at about $30.38 ($273K), marked as a 10b5-1 plan trade. Holdings down 11% to 69,740 shares. | SEC filing Filed Nov 3, 2025 |
54 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
| Filed | Items | Tag | Source |
|---|---|---|---|
| Nov 3, 2026, 8:09 AM ET 8-K | Earnings released (Item 2.02) | SEC filing |
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow ALKS in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.